Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma

INTRODUCTION: Before the approval of enfortumab vedotin, no standard treatment was available as the salvage treatment for patients with metastatic urothelial carcinoma who had failed second‐line or later pembrolizumab. Pembrolizumab rechallenge is one of the options for these patients, but there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Nobutaka, Miyake, Makito, Shimizu, Takuto, Tachibana, Akira, Tanaka, Nobumichi, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436659/
https://www.ncbi.nlm.nih.gov/pubmed/36090940
http://dx.doi.org/10.1002/iju5.12474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436659/
https://www.ncbi.nlm.nih.gov/pubmed/36090940
http://dx.doi.org/10.1002/iju5.12474

Ejemplares similares